Tessa Jowell BRAIN MATRIX - Platform Study
ConditionGlioma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorUniversity of Birmingham
About this trial
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Eligibility criteria
Qualifiers
Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
Valid written informed consent for the study.
Disqualifiers
Primary spinal cord tumours
Active treatment of other malignancy
Contraindication to MRI
Patients without standard of care imaging available
Trial design
Treatments tested in this trial
- Matched Tumour and Blood Sample - Research Pathway
- Matched Tumour and Blood Sample - NHS GMS pathway
Treatment groups
No treatment groups listed
Sponsors and collaborators
University of Birmingham
Lead sponsor
The Brain Tumour Charity
Collaborator
University of Oxford
Collaborator
University of Edinburgh
Collaborator
Genomics England
Collaborator
Source ClinicalTrials.gov